[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100641189":3},{"organization":4,"outcomesModule":7,"designInfo":14,"detailedDescription":13,"studyPopulation":17,"armGroups":13,"interventions":13,"overallOfficials":18,"centralContacts":23,"locations":33,"responsibleParty":68,"collaborators":13,"id":70,"slug":13,"hasResults":71,"nctId":72,"briefTitle":73,"officialTitle":73,"acronym":13,"eligibilityCriteria":74,"healthyVolunteers":71,"sex":75,"minAge":76,"maxAge":13,"enrollmentInfo":77,"targetDuration":80,"studyType":81,"phases":13,"briefSummary":82,"conditions":83,"keywords":13,"overallStatus":35,"whyStopped":13,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"University Hospital, Basel, Switzerland","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":13},[9],{"measure":10,"description":11,"timeFrame":12},"Detectability of ct-DNA in T1G3 urothelial bladder cancer patients","Primary endpoint is the detectability of ct-DNA in T1G3 urothelial bladder cancer patients, whether there are dynamic changes during the different treatment steps (after TUR-BT, after re-TUR-BT, during instillation therapy) and if ct-DNA is predictive \u002F prognostic in T1G3 urothelial bladder cancer patients.","From start of treatment 36 Months",null,{"allocation":13,"interventionModel":13,"interventionModelDescription":13,"primaryPurpose":13,"observationalModel":15,"timePerspective":16,"maskingInfo":13},"COHORT","PROSPECTIVE","Patients with a proven T1G3 Bladder Cancer",[19],{"name":20,"affiliation":21,"role":22},"Cyrill Rentsch, Prof.","Universitätsspital Basel","PRINCIPAL_INVESTIGATOR",[24,29],{"name":25,"role":26,"phone":27,"phoneExt":13,"email":28},"Heike Püschel","CONTACT","+41 61 55 65477","Heike.Pueschel@usb.ch",{"name":30,"role":26,"phone":31,"phoneExt":13,"email":32},"Niklas Simon","+41 61 55 65616","niklas.simon@usb.ch",[34,51],{"facility":21,"status":35,"city":36,"state":13,"zip":13,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"RECRUITING","Basel","Switzerland","CH",{"type":40,"coordinates":41},"Point",[42,43],7.57327,47.55839,{"lat":43,"lon":42},[46,47,49],{"name":25,"role":26,"phone":27,"phoneExt":13,"email":28},{"name":30,"role":26,"phone":31,"phoneExt":13,"email":48},"Niklas.Simon@usb.ch",{"name":50,"role":22,"phone":13,"phoneExt":13,"email":13},"Cyrill Rentsch",{"facility":52,"status":35,"city":53,"state":13,"zip":13,"country":37,"countryCode":38,"cosmosGeoPoint":54,"geoPoint":58,"contacts":59},"Luzerner Kantonsspital","Lucerne",{"type":40,"coordinates":55},[56,57],8.30635,47.05048,{"lat":57,"lon":56},[60,63,66],{"name":61,"role":26,"phone":13,"phoneExt":13,"email":62},"Fabian Aschwanden","fabian.aschwanden@luks.ch",{"name":64,"role":26,"phone":13,"phoneExt":13,"email":65},"Tamara Lötscher","tamara.loetscher@luks.ch",{"name":67,"role":22,"phone":13,"phoneExt":13,"email":13},"Nico Grossmann",{"type":69,"investigatorFullName":13,"investigatorTitle":13,"investigatorAffiliation":13,"oldNameTitle":13,"oldOrganization":13},"SPONSOR","100641189",false,"NCT07581496","T1G3R-1 Trial: Detectability and Prognostic Value of ctDNA in T1 G3 Bladder Cancer","Inclusion Criteria:\n\n* patients \\> 18 years of age, able to give informed consent as documented by signature,\n* patients with a cystoscopically proven bladder cancer, suspicious for T1 stage, who will undergo TUR-B\n\nExclusion Criteria:\n\n* Patients with metastases or concomitant upper tract tumor at diagnosis will\n* Patients with non T1 G3 cancers\n* Patients with upstaging, either at re-TUR-B or after immediate radical cystectomy\n* Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc.\n* Vulnerable persons (e.g. \\\u003C 18y of age, unable to consent to the study)","ALL","18 Years",{"count":78,"type":79},35,"ESTIMATED","3 Years","OBSERVATIONAL","T1G3 bladder cancer is a heterogeneous disease with a high risk of disease persistence after the first TUR-B, understaging, disease progression, bladder removal, and mortality.\n\nCurrent risk stratification is insufficient and needs improvement. Ct-DNA could identify patients with disease persistence, progression and could monitor and tailor therapy. It might improve patient risk stratification, avoiding under- and overtreatment, reducing morbidity and mortality.\n\nPrimary objective is to investigate the detectability of ct-DNA in T1G3 urothelial bladder cancer patients and build a biobank through collection of different sample types (urine, plasma) in T1G3 bladder cancer patients which allows future retrospective testing.",[84],"Bladder Cancer","2026-05-14",{"date":87,"type":88},"2026-05-18","ACTUAL",{"date":90,"type":88},"2025-06-18",{"date":92,"type":79},"2030-06-01",{"name":5,"class":6},2]